The Use of Peripheral Blood-Mononuclear Cells in Scleroderma Patients: An Observational Preliminary Study

Sara Carella*
Caterina Rossi
Diego Ribuffo
Maria Giuseppina Onesti

1Department of Surgery “Pietro Valdoni”, Unit of Plastic Surgery, Sapienza University of Rome, Italy

Abstract

Introduction: Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by vasculopathy and excessive production of collagen, which lead to skin and visceral fibrosis. The aim of our study is to assess the potential benefits of autologous peripheral blood mononuclear cells (PBMCs) implants in the treatment of clinical manifestations such as mouth impairment, hand disability, digital ulcers and Raynaud’s phenomenon in Scleroderma patients.

Methods: From February 2016 to May 2019, 10 female patients were enrolled from the outpatient clinic of the Plastic Surgery Unit of Sapienza University of Rome. Parameters evaluated were: patients’ disability, using the Health Assessment Questionnaire (HAQ) disability index (DI) and the scleroderma HAQ (sHAQ); mouth opening capacity, by measuring the maximum interincisal distance and the mouth perimeter; hand mobility, assessed with clinical exam and the Hand Mobility in Scleroderma (HAMIS) scale; Raynaud’s phenomenon, evaluated through nailfold capillaroscopy; digital ulcers, examined through their features and incidence of appearance. SPSS software was used for a simple descriptive statistical analysis performed by the Student’s paired t-test. P values less than 0.05 were considered statistically significant.

Results: The treatment showed a significant improvement of all the parameters evaluated at 1-year follow-up, it was well-tolerated by all the patients and the only complications noticed were small areas of ecchymosis.

Conclusions: With our preliminary study we sought to exploit PBMCs capability to induce angiogenesis widely described in literature in order to treat the vasculopathy-related manifestations of SSc, in patients with no chance for lipofilling. Our results suggest that PBMCs injection could represent a treatment option to take into account for SSc patients. The procedure we used is easy and fast to perform, minimally invasive and not-operator dependent. We hope our observational and preliminary study could be considered as a starting point for further research studies.

Keywords: Peripheral Blood Mononuclear Cells, Macrophages, Immunomodulation, Systemic sclerosis, Cell Therapy, Wound Healing.

List of Abbreviations: SSc: Systemic sclerosis; PBMCs: peripheral blood mononuclear cells; HAQ-DI: Health Assessment Questionnaire Disability Index; sHAQ: scleroderma Health Assessment Questionnaire; HAMIS: Hand Mobility in Scleroderma; ACR: American College of Rheumatology; ACR/EULAR: American College of Rheumatology/European League Against Rheumatism; SVF: Stromal Vascular Fraction;
Introduction

Systemic sclerosis (SSc) is a systemic autoimmune disease of unknown cause characterized by vasculopathy and excessive production of collagen [1]. Several pathophysiological processes are involved in its development such as cellular and humoral autoimmunity, vascular injury, and tissue fibrosis. They all lead to a connective tissue disease characterized by a pathological thickening and tethering of the skin and by the involvement of internal organs (gastrointestinal tract, heart, lungs and kidneys) [2].

Due to its low-frequency, insidious onset, variable presentation and the lack of uniformity in its diagnostic criteria, it is difficult to study its epidemiological features. However, its prevalence ranges from 7/million to 489/million and its incidence from 0.6/million-year to 122/million-year [2]. There are many geographical variations, with higher prevalence in the USA and Australia, followed by Japan and Europe. Age of onset is most commonly in the range of 30–50 years. The prevalence in first degree relatives is significantly higher than in the general population (1.6 vs 0.026%) and like other connective tissue disorders, SSc is also predominant in females with ratios of women to men between 5 and 14:1 [3].

The ACR (American College of Rheumatology) criteria published in 1980 were the first used to classify these patients, but the 2013 EULAR (European League Against Rheumatism)/ACR classification criteria showed a higher sensitivity. The ACR criteria are limited by their lack of sensitivity for mild and early cases of SSc [4].

The term “Scleroderma” derives from the most characteristic feature of the disease – skin thickening. Raynaud’s phenomenon occurs as the first clinical feature of the pathology, simultaneously with skin thickening or shortly prior to it. It is typically present in the digits of the hand but can also affect the feet, the earlobes, the tip of the nose and the tongue. In Scleroderma patients it often leads to the onset of trophic changes in the fingertips, in the form of necrosis, hard-to-heal erosions and ulcers, and residual scars. Finger contractures (sclerodactyly) develop with the progression of the disease. The range of finger motion is limited, while trophic disorders contribute to bone destruction and shortening of distal phalanges (acroosteolysis) [5].

Restricted hand movements include finger flexion and extension, abduction of the thumb, dorsal extension and volar flexion of the wrist, pronation and supination of the forearm, ability to make a thumb pincer grip and to make finger abduction [1-5].

Skin sclerosis may also affect the face, including the lips. The most typical facial features associated with SSc are telangiectasias, shrunken nose, microcheily, reduced mouth opening (microstomy), and microglossy. In addition, cutaneous wrinkles around the mouth disappear and there may be a radial furrowing around the lips: the face of these patients appears inexpressive. Among other skin manifestations there are changes in skin pigmentation, hair loss, dryness due to the loss of sebaceous glands, and joint contracture [1-5].

Facial involvement and oral complications can lead to problems with oral hygiene and eating, aesthetic changes and impairment of the patient’s self-image. Moreover, sclerosis of the extremities is highly disabling and results in significant dysfunction. Due to these disabilities, several studies are concordant in remarking the importance of a multidisciplinary therapy and tailored approach. The usefulness of pharmacological, pathogenetic and symptomatic treatments (immunosuppressor, immunomodulators, antifibrotics, corticosteroids, plasmapheresis, phototherapy, anti-inflammatory, vasoactive, and analgesic drugs), as well as some precautionary measures and a proper life-style (such as avoiding cold or smoke), may be important to prevent and treat Scleroderma skin lesions [6].

In addition to these systemic approaches, local treatments should be considered in more severe and non-healing lesions [6]. Several regenerative cell-based techniques were described for the treatment of Scleroderma patients, mostly with autologous fat (lipofilling), stromal vascular fraction (SVF) and/or adipose-derived stem cells (ASCs) from adipose tissue [7-12].

New point of care device based on peripheral blood selective filtration technology has been developed to produce fresh autologous peripheral blood mononuclear cells (PBMCs) for use in human cell therapy applications. Cell concentrate produced by this innovative technology has been extensively studied in term of characterization and adequate potency in therapeutic angiogenesis in vitro and in vivo [13]. This technique is less invasive in comparison to adipose tissue transplantation, faster, not operator-dependent and user-friendly. Promising results on wound healing were obtained by this cellular concentrate in different clinical trials on critical limb ischaemia patients, [14-16]. It has been observed that PBMCs are able to induce therapeutic angiogenesis to promote collateral vessel formation through paracrine effects [17,18]. PBMCs release growth factors, cytokines, messenger molecules as well as exosomes, demonstrated in a wound healing animal model [19-21]. Monocyte/macrophages and lymphocytes, in particular Treg populations, play a key role in tissue regeneration in non-healing trophic lesions through macrophage polarization from an inflammatory (M1) to regenerative (M2) phenotype [22]. Growing evidence also suggests a key role of lymphocytes in angiogenesis and in tissue regeneration [23-26]. PBMCs could have an indication of use in autoimmune-based diseases where there is a vascular and/or microcirculation problem [27-29] not only for their angiogenic capacity but also for their ability to regenerate tissues and restore the correct M1/M2 balance, always compromised in the non-healing lesions of patients suffering from these pathologies, as recently published [30].

For the first time at the best of our knowledge we report the experience on the use of PBMCs implants in order to
treat open mouth impairment, hand disability, digital ulcers and Raynaud’s phenomenon.

Primary outcomes were: improvement of hand function and mouth opening. The secondary outcome was the gaining of a better quality of life.

Methods

From February 2016 to May 2019, 10 female patients, fulfilling ACR criteria and classified as having diffuse cutaneous Scleroderma (dcSSc), were enrolled from the outpatient clinic of the Plastic Surgery Unit of Sapienza University of Rome [31-33]. These patients had advanced SSC-related perioral thickening, mouth opening restriction (2 out of 10 patients) and hand mobility limitation, Raynaud’s phenomenon, and digital ulcers. The proposed treatment consisted of PBMCs injections in order to treat the above manifestations. The mean age was 50.2 years (range: 21-68) and the average disease length was 7 years (range: 3-11). They agreed by a written informed consent to participate in the study, which was conducted in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki.

For each patient, during the first evaluation, demographic, anamnestic, and clinical data were collected and recorded, using a written form that was held securely, thus being accessible only to investigators involved in the study (Table 1).

Inclusion criteria

Age >18 years, stable phase of disease, SSc diagnosis with hands and/or perioral involvement; no possibility to perform lipolifting (lack of adipose tissue, BMI<20).

Exclusion criteria

Age>75 years, pregnancy, or lactation; immunomodulating or immunosuppressive therapy within the last 4 weeks and any topical therapy within the last 2 weeks except for the use of emollients, comorbidities contraindicating the treatment (active malignancy, bone marrow or hematologic disorders, active infections).

Disability evaluation

All patients were evaluated for the following parameters before the procedure (T0), and 1 week (T1), 1 month (T2), 3 months (T3), 6 months (T4) and 1 year (T5) after.

Health Assessment Questionnaire (HAQ) Disability Index (DI) and scleroderma HAQ (sHAQ): These instruments are increasingly utilized to assess Scleroderma patients in randomized trials. The HAQ-DI contains 8 domains of activity (dressing, arising, eating, walking, hygiene, reach, grip, and common daily activities) each of which has at least 2 questions, for a total of 20 items. For each item patients report the amount of difficulty experienced performing the activity with 4 possible responses, ranging from 0 (without any difficulty) to 3 (unable to do). The highest component score in each category determines the score for the category. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no impairment in function) to 3 (maximal impairment of function). The scale is not truly continuous. The HAQ-DI also contains a Visual Analogue Scale (VAS) that patients use to report the amount of pain experienced in the past week (Figure 1) [34]. The sHAQ is more specific for Ssc, as it adds 5 visual analogue scales to HAQ, evaluating also Raynaud’s phenomenon, digital ulcers, gastrointestinal, lung symptoms, and overall disease severity [35].

Mouth opening capacity [12]: it was evaluated by measuring, at baseline and at each follow-up, the maximum interincisal distance and the mouth perimeter. This latter one was derived by the ellipse geometrical formula, that is $2\pi\sqrt{(a^2+b^2)/2}$, where “a” stands for the semi-major axis (half of the distance between upper and lower lip, at maximally opened mouth), and “b” stands for the semi-minor axis (half of the distance between the opposite lip commissures) (See Figures 4A-B). The software used was Microsoft Mathematics 4.0.

Hand Mobility in Scleroderma (HAMIS): this is a performance-based test, found to be a reliable and valid tool to assess hand function in Ssc patients. It is composed of 9 items, assessing both hands (Table 2). The different performance areas of HAMIS test are composed of different-sized grips and different movements, all related to tools and activities that are part of daily occupations. Each exercise is graded on a 0–3 scale (from 0 = normal function to 3 = inability to perform the task), with a total possible score of 27 for each hand [36] (Table 2).

Raynaud’s phenomenon: its frequency and duration were assessed through patient reported data and its severity with nailfold capillaroscopy.

Cutaneous digital ulcers: they were examined through anamnestic and clinical findings. Their incidence of appearance was recorded.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Disease duration</th>
<th>Treated area</th>
<th>PBMCs concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>68</td>
<td>6 years</td>
<td>Hands</td>
<td>Innovations</td>
</tr>
<tr>
<td>2</td>
<td>65</td>
<td>11 years</td>
<td>Hands</td>
<td>Innovations</td>
</tr>
<tr>
<td>3</td>
<td>49</td>
<td>8 years</td>
<td>Hands and mouth</td>
<td>Innovations</td>
</tr>
<tr>
<td>4</td>
<td>47</td>
<td>8.5 years</td>
<td>Hands</td>
<td>Innovations</td>
</tr>
<tr>
<td>5</td>
<td>39</td>
<td>4.5 years</td>
<td>Hands</td>
<td>Innovations</td>
</tr>
<tr>
<td>6</td>
<td>50</td>
<td>6 years</td>
<td>Hands</td>
<td>Innovations</td>
</tr>
<tr>
<td>7</td>
<td>44</td>
<td>7 years</td>
<td>Hands</td>
<td>Innovations</td>
</tr>
<tr>
<td>8</td>
<td>21</td>
<td>3 years</td>
<td>Hands</td>
<td>Innovations</td>
</tr>
<tr>
<td>9</td>
<td>56</td>
<td>9 years</td>
<td>Hands and mouth</td>
<td>Innovations</td>
</tr>
<tr>
<td>10</td>
<td>63</td>
<td>7 years</td>
<td>Hands</td>
<td>Innovations</td>
</tr>
</tbody>
</table>

Table 1: Patients’ data.
Hand Mobility In Scleroderma (HAMIS) test.

Table 2. Hand Mobility In Scleroderma (HAMIS) test.

**Finger flexion**
(All fingers must be tight to the object)
0 - Can bend fingers 2-5 around a pencil (5 mm diam)
1 - Can bend fingers 2-5 around a piece of cutlery (15 mm diam)
2 - Can bend fingers 2-5 around handlebar (30 mm diam)
3 - Cannot manage the previous item

**Finger extension**
0 - Can feel the table completely with digits 2-5
1 - Can feel the pencil (5 mm diam) with digits 2-5
2 - Can feel the piece of cutlery (15 mm diam) with digits 2-5
3 - Cannot manage the previous item

**Thumb abduction**
0 - Can grip around a coffee package (90 mm diam)
1 - Can grip around a milk parcel (70 mm diam)
2 - Can grip around a bottle (60 mm diam)
3 - Cannot manage the previous item

**Pincer grip**
0 - Can form a round pincer grip
1 - Can form a D-shaped pincer grip
2 - Can form a long narrow pincer grip
3 - Cannot manage the previous item

**Finger abduction**
0 - Can spread the fingers and then fold the hands together to the bottom of the fingers
1 - Can spread the fingers and then fold the hands together to the first phalanx
2 - Can spread the fingers and then fold the hands together to the second phalanx
3 - Cannot manage the previous item

**Volar flexion**
(The person stands with the arms alongside the body. The object is given from behind)
0 - Can grasp a spool of thread with a slight flexion of MCP and extended PIP and DIP joints
1 - Can grasp a spool of thread with a large flexion of MCP and extended PIP and DIP joints
2 - Can grasp a spool of thread with a large flexion of MCP and flexion PIP
3 - Cannot manage the previous item

**Dorsal extension**
0 - Can hold the palms together and put the wrists against the stomach
1 - Can hold the palms together and put the thumbs against the throat
2 - Can hold the palms together and put the thumbs up to the mouth
3 - Cannot manage the previous item

**Pronation**
0 - Can put the palms of the hands on the table (MCP 2-5 must touch the surface)
1 - Can put the palms of the hands on the table (MCP 3-5 must touch the surface)
2 - Can put the palms of the hands on the table (MCP 4-5 must touch the surface)
3 - Cannot manage the previous item

**Supination**
0 - Can put the backs of the hands on the table (MCP 2-5 must touch the surface)
1 - Can put the backs of the hands on the table (MCP 3-5 must touch the surface)
2 - Can put the backs of the hands on the table (MCP 4-5 must touch the surface)
3 - Cannot manage the previous item

MCP: Metacarpophalangeal joints, PIP: Proximal interphalangeal joints, DIP: Distal interphalangeal joints

In a sterile-operating environment PBMCs were obtained from a 100-120 mL venous blood sample following the original instruction for use. The procedure was performed as follows: 120 mL of ACD (Acid Citrate Dextrose) anticoagulated blood were transferred to the upper bag of the system which was hung up to let the blood flow by gravity through the filter below. The selective membrane retained TNCs and the residual blood flowed to the waste blood bag under the filter. After filtration, which took around 10-15 min, a 10 mL of saline solution backwash allowed to harvest the PBMCs from the filter, resulting in 8-10 mL of cell concentrate collected in a cell recovery bag and ready to be injected. Equal parts (0.25 mL) of the cell concentrate obtained were injected in each site, containing a mean average count of 20,8±0.1*10^6/mL TNC, 10,6±0.2*10^6 MNC and 137±0.3*10^6/mL CD34+ [13].

**Cell therapy: autologous PBMCs implants**

For hands, each injection was performed with a 21 G needle. Subcutaneous injections were performed at the bases of the fingers and proximally to the digital ulcers at perilesional skin level. The total amount of cell concentrate we injected varied from 3 to 5 mL, depending on each selective case. For mouth, injections were performed at subcutaneous level of selected perioral areas, using a blunt cannula of 2 mm in diameter. The cannula was inserted in 2 symmetric sites located just proximally to the labial commissures. Six areas were identified: two in the upper lip and two in the lower lip (two lateral for each lip). The remaining 2 areas were represented from the nasolabial fold and a line extending from the labial commissure toward mandibular border. Perioral region was injected using as many radiating passages at subcutaneous level as needed for a total of 2 mL.

The study design foresaw the performance of the treatment once a month, for a total of 3 to 4 sessions, to be evaluated depending on the single case outcome.

**Statistical analysis**

SPSS software (IBM Corp., Armonk, NY) was used for a simple descriptive statistical analysis. Absolute scores and their changes from T0 to T5 were evaluated. The Shapiro–Wilk test was used to verify the normal distribution of continuous variables. Consequently, data were analyzed using Student’s paired t-test. P values less than 0.05 were considered statistically significant.

**Results**

The treatment showed a significant improvement of all the parameters evaluated (Table 3). In all patients HAMIS scale decreased (p = 0,0026), reflecting a better hand function. The frequency of Raynaud’s phenomenon appeared to be reduced (p = 0,0023): in one
patient especially there was a reduction from an average of 15 episodes per day to a maximum of 5 episodes per day after the PBMCs therapy. Six patients were affected by multiple digital ulcers at baseline, after 12 months from the autologous implant only three of them had one digital ulcer left ($p = 0.0044$) (Figures 3A-B).

The improvement of mouth opening was observed in two patients: an increased mouth perimeter was recorded (patient A mouth perimeter: from T0 = 10.84 to T5 = 13.66; patient B mouth perimeter: from T0 = 9.72 to T5 = 12.87) (Figures 4A-B). Patients referred improving in oral hygiene and bite function.

We also recorded a meaningful decrease of the HAQ-DI composite score ($p = 0.0017$).

The treatment was well-tolerated by all the patients, the only complications noticed were small areas of ecchymosis. Three patients claimed to be very satisfied with the procedure, five claimed to be satisfied, and two were moderately satisfied.

<table>
<thead>
<tr>
<th>Patient</th>
<th>HAMIS Scale1 (0-27)</th>
<th>Raynaud’s phenomenon (episodes per day)</th>
<th>Digital ulcers (annual incidence)</th>
<th>HAQ-DI score2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>T0 (right/left)</td>
<td>T5 (right/left)</td>
<td>T0</td>
<td>T5</td>
</tr>
<tr>
<td>1</td>
<td>10/10</td>
<td>4/4</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>6/6</td>
<td>2/2</td>
<td>9</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>8/8</td>
<td>3/3</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>11/11</td>
<td>7/7</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>7/7</td>
<td>2/2</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>6/6</td>
<td>2/2</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>9/9</td>
<td>3/3</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>7/7</td>
<td>3/3</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>8/8</td>
<td>4/4</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>9/9</td>
<td>6/6</td>
<td>9</td>
<td>4</td>
</tr>
</tbody>
</table>

1 Hand Mobility In Scleroderma (HAMIS) Scale
2 Health Assessment Questionnaire (HAQ) Disability Index (DI)

Table 3: Patients’ clinical outcomes.

Figure 1: Health Assessment Questionnaire (HAQ) Disability Index (DI).
**Figure 2:** Pall Celeris system. A.) Filter’s components. B.) Step 1: 120 mL of ACD (Acid Citrate Dextrose) anticoagulated blood are transferred to the upper bag of the system. C.) Step 2: the system is hung up to let the blood flow by gravity through the filter below. D.) Step 3: the selective membrane retains TNCs and the residual blood flows to the waste blood bag under the filter. E.) Step 4: after filtration, which takes around 10-15 min, a 10 mL of saline solution backwash allows to harvest the PBMCs from the filter, resulting in 8-10 mL of cell concentrate collected in a cell recovery bag and ready to be injected.


**Figures 4A-B:** Evolution of mouth impairment with treatment. A.) Pre-treatment appearance in patient with mouth opening impairment. Patient A – T0: half of the distance between the lip commissures (red line): 2 cm; half of the distance between upper and lower lip (blue line): 1.45 cm. Ellipse Perimeter = 10.84 cm. B.) Post-treatment appearance in patient with mouth opening impairment: improvement of mouth opening. Patient A – T5: half of the distance between the lip commissures (red line): 2 cm; half of the distance between upper and lower lip (blue line): 2.35 cm. Ellipse Perimeter = 13.66 cm.
Discussion

Over the years several alternatives to treat the cutaneous and vasculopathy-related manifestations of SSC were suggested. Autologous fat transplantation has become the first-choice technique for treating SSC cutaneous lesions. This approach, using the patient’s own body fat as a natural filler to achieve structural modifications, takes advantage of its abundance and accessibility and avoids complications associated with foreign materials. Elective liposuction for fat transplantation is nowadays considered a safe and well-tolerated procedure. Unfortunately, adipose tissue is not available in every patient, as it happens for patients with low BMI (< 20) [12].

Nevertheless, some studies described the potential role of cell-based therapies, such as ASCs and SVF based therapy [10-12]. They require less invasive harvesting techniques than the ones used when bone marrow is the primary source of mesenchymal stromal cells (MSCs) and are particularly useful in SSC patients with a degree of skin fibrosis that could not even permit the insertion of the smallest liposuction cannula.

Moreover, point-of-care devices have been placed on the market for the production of micro fragmented adipose tissue, also called nano graft, and adipose cells concentration system containing SVF [37].

The main disadvantages of ASCs-based therapy are represented by high costs, due to cell preparation in certified Good Manufacturing Practice (GMP) laboratories, and its need to be performed in two separate sessions, thus increasing the patient discomfort.

Notably, several papers showed that a main mechanism of action of ASCs from adipose tissue is to promote tissue regeneration through M2 polarization, but hypoxia reduces their capability to polarize macrophages in the M2 phenotype while for PBMCs hypoxia is a physiological trigger for angiogenesis [38-46].

Moreover, Navarro et al recently showed that the angiogenic capacity of adipose tissue is related to the monocytes CD14+ population contained in SVF, which is more efficient in inducing angiogenesis than the ASCs [47].

PBMCs represent a new promising autologous therapy used in critical limb ischemia, diabetic foot and chronic ulcers [14-16,48-53]. The angiogenic and arteriogenic capacity of monocytes is well described [17,18,20,21,54]. More recently several studies also indicate an angiogenic function of specific limphocytes populations [25,55-58].

It is interesting to note that PBMCs efficacy was also reported in a large meta-analysys in no-option critical limb ischemia patients showing that PBMCs may outperform bone marrow–mononuclear cells and mesenchymal stem cells in reducing significatively limb amputation [48].

With our preliminary study we sought to exploit PBMCs capability to induce angiogenesis widely described in literature in order to treat the typical vasculopathy-related manifestations of SSC, in patients with no chance for lipofilling [21,59-61].

The selective filtration based technology we used produces an autologous cell concentrate wich contains PBMCs plus around 1% of CD34+ [13]. Despite that the efficiency in CD34+ hematopoietic stem cell enrichment with the use of Bone Marrow Point of Care system is comparable to the enrichment obtained by Pall Celeris system, several studies showed that limb salvage did not correlate to CD34+ concentration [16,48,62-64].

In addition to their angiogenic ability, PBMCs mechanism of action is based also on tissue regeneration due to immune-modulation and paracrine release of growth factors, cytokines and chemokines [19,20].

Monocytes give rise to mature macrophages which are also heterogeneous themselves, although the physiological relevance of this is not completely understood [65]. Macrophages display a wide range of phenotypes and physiological properties depending on the cytokines inducing their maturation [66]. They can adopt a variety of different phenotypes in response to different stimuli. Two of the best-characterized in vitro phenotypes are a proinflammatory "M1" phenotype, produced by exposure to IFN-γ and TNF-α and hypoxia, and an anti-inflammatory "M2" phenotype, produced by IL-4 or IL-13 [30]. M1 is the predominant population present during the first few days after injury, corresponding to the inflammatory and early proliferative phases, whereas M2 population is the primary effector of the later stages of repair or the later proliferative and remodeling phases. In fact, M2 are frequently termed “wound healing” macrophages, as they express factors that are important for tissue repair [30,67,68].

Macrophages interact with other cell types through paracrine factors to control reepithelialisation, angiogenesis and extracellular matrix remodelling, and several studies have analysed the difficulties in skin wound healing upon macrophage depletion [69-72]. Macrophages play key roles in tissue homeostasis and immune surveillance in response to microbial assault and are fundamental in promoting wound healing to repair damaged tissue [22,73]. Failure to resolve macrophage activation can lead to chronic inflammation and fibrosis, and ultimately to disease generation. PBMCs implant induces tissue regeneration through immune-modulation (M1 to M2 polarization) [22,51,74,75]. In particular PBMCs produced by selective filtration implanted perilesionally in non healing diabetic foot ulcers were able to polarize M1 to M2 phenotype inducing complete healing [51]. Activated M1 macrophages have been implicated in the pathogenesis of SSC [54,55]. Therefore targeting therapeutic interventions directed against SSC inflammatory M1 macrophages may ameliorate inflammation and fibrosis [76].

PBMCs ability to induce the shift from M1 to M2 causing tissue regeneration could explain the results we obtained regarding the healing of the digital ulcers. We recorded a lower frequency of Raynaud’s phenomenon, together with a significant improvement in hand function. We also observed a mouth opening improvement in the two patients who received the treatment in this area. Furthermore, we observed a significant improvement of all the parameters
evaluated, including a meaningful decrease of the HAQ-DI composite score.

Two aspects of this work have to be resolved in future studies: the low number of treated patients, and the fact that this is a preliminary and observational study lacking a control group. Despite this, the preliminary results on these critical patients, non-responders to standard therapies and with no chance for lipofilling, are encouraging. Our results are in agreement with the observations found in two case reports showing an improvement in vascularization and digital ulceration in SSc patients [77,78]. Results are also in line with suggestive result of PBMCs on others auto-immune disease like Thromboangiitis Obliterans [16,77].

Conclusion

The great vasculogenic/angiogenic capacity of monocytes/macrophages together with their key role in immune-modulation have been demonstrated in numerous different clinical settings [79-85]. On the whole, evidence highlights M1 and M2 macrophages as important targets for immunotherapy [30]. In our preliminary study, PBMCs injection effectively increased all the primary outcomes of the study despite a low level of evidence due to the small sample size. These results suggest that PBMCs injection could represent a treatment option for SSc patients. The procedure we used, is easy and fast to perform, minimally invasive, not-operator dependent, safe and effective in treating mouth opening, Raynaud’s phenomenon, digital ulcers and hand movement impairment. Further studies are necessary to confirm these preliminary positive outcomes.

Declarations

Ethics approval and consent to participate

Patients agreed to participate in the study by signing a written informed consent.

The study was conducted in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki. This study is part of a project approved by Sapienza University of Rome.

Consent for publication

Consent for publication was obtained from all the patients.

Availability of data and materials

The data that support the findings of this study are available on request from the corresponding author, [S.C.]. The data are not publicly available because the containing information could compromise the privacy of the research participants.

Competing interests

The authors declare that they have no competing interests regarding the publication of this article.

Funding Statement

The authors received no specific funding for this work.

Authors’ contribution

All Authors read and approved the manuscript. S.C. enrolled the patients and was a contributor in treating the patients. She drafted and revised the manuscript. C.R. analyzed and interpreted the patient data regarding the Scleroderma, the treatment and the follow-up visits. She was a major contributor in writing the manuscript. D.R. read and approved the manuscript. M.G.O. performed the treatment and revised and approved the manuscript.

Acknowledgement

Not applicable.

References


